Editas Medicine EDIT
Editas Medicine, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)
$2.95+13.46%close on Oct. 28, 2026 · volume 4.4M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 3, 2026 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Sold 10b5-1 plan | 709 | $3.04 | $2,153 |
| Sept. 3, 2026 | Amy Parison SVP, Chief Financial Officer | Sold 10b5-1 plan | 453 | $3.04 | $1,376 |
| Sept. 3, 2026 | Gilmore Neil O'Neill CEO, director | Sold 10b5-1 plan | 5,124 | $3.04 | $15,563 |
| Aug. 3, 2026 | Amy Parison SVP, Chief Financial Officer | Sold 10b5-1 plan | 678 | $2.58 | $1,749 |
| July 28, 2026 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Sold 10b5-1 plan | 4,928 | $2.67 | $13,158 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 13 →Regulation FD disclosure · Other events · Financial statements and exhibits